Aligos Therapeutics, Inc.
ALGS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3,945 | $15,529 | $13,907 | $4,359 |
| % Growth | -74.6% | 11.7% | 219% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $3,945 | $15,529 | $13,907 | $4,359 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $70,269 | $73,040 | $85,077 | $104,153 |
| G&A Expenses | $22,830 | $30,616 | $26,410 | $28,527 |
| SG&A Expenses | $22,830 | $30,616 | $26,410 | $28,527 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $93,099 | $103,656 | $111,487 | $132,680 |
| Operating Income | -$89,154 | -$88,127 | -$97,580 | -$128,321 |
| % Margin | -2,259.9% | -567.5% | -701.7% | -2,943.8% |
| Other Income/Exp. Net | -$41,726 | $1,243 | $1,640 | $132 |
| Pre-Tax Income | -$130,880 | -$86,884 | -$95,940 | -$128,189 |
| Tax Expense | $331 | $795 | $106 | $143 |
| Net Income | -$131,211 | -$87,679 | -$96,046 | -$128,332 |
| % Margin | -3,326% | -564.6% | -690.6% | -2,944.1% |
| EPS | -20.94 | -3.52 | -2.25 | -3.22 |
| % Growth | -494.9% | -56.4% | 30.1% | – |
| EPS Diluted | -20.94 | -3.52 | -2.25 | -3.22 |
| Weighted Avg Shares Out | 6,265 | 24,873 | 42,695 | 39,855 |
| Weighted Avg Shares Out Dil | 6,265 | 24,873 | 42,695 | 39,855 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,670 | $1,243 | $1,640 | $132 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2,622 | $3,069 | $3,675 | $3,778 |
| EBITDA | -$86,532 | -$85,058 | -$93,905 | -$124,543 |
| % Margin | -2,193.5% | -547.7% | -675.2% | -2,857.1% |